MADRID — Roche’s next-gen KRAS G12C inhibitor cut the risk of death by 44% in previously treated mutant non-small cell lung cancer in a head-to-head trial …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.